265 related articles for article (PubMed ID: 16625144)
1. Deferasirox (Exjade): a new iron chelator.
Med Lett Drugs Ther; 2006 Apr; 48(1233):35-6. PubMed ID: 16625144
[No Abstract] [Full Text] [Related]
2. Deferasirox--an oral agent for chronic iron overload.
Vanorden HE; Hagemann TM
Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
Imran F; Phatak P
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of deferasirox.
Cappellini MD
Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
[TBL] [Abstract][Full Text] [Related]
5. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
6. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
[TBL] [Abstract][Full Text] [Related]
7. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
Cappellini MD; Taher A
Expert Opin Pharmacother; 2008 Sep; 9(13):2391-402. PubMed ID: 18710363
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
9. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
Kontoghiorghes GJ
Hemoglobin; 2008; 32(6):608-15. PubMed ID: 19065341
[No Abstract] [Full Text] [Related]
10. Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.
Kontoghiorghes GJ
Expert Opin Drug Saf; 2008 Nov; 7(6):645-6. PubMed ID: 18983212
[TBL] [Abstract][Full Text] [Related]
11. A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia.
Kennedy GA; Morris KL; Subramonpillai E; Curley C; Butler J; Durrant S
Br J Haematol; 2013 Jun; 161(6):794-801. PubMed ID: 23590671
[TBL] [Abstract][Full Text] [Related]
12. Current status of iron overload and chelation with deferasirox.
Choudhry VP; Naithani R
Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
[TBL] [Abstract][Full Text] [Related]
13. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Porter JB; Taher AT; Cappellini MD; Vichinsky EP
Hemoglobin; 2008; 32(6):601-7. PubMed ID: 19065340
[No Abstract] [Full Text] [Related]
14. Acute renal failure and Fanconi syndrome due to deferasirox.
Grangé S; Bertrand DM; Guerrot D; Eas F; Godin M
Nephrol Dial Transplant; 2010 Jul; 25(7):2376-8. PubMed ID: 20466673
[TBL] [Abstract][Full Text] [Related]
15. The oral chelator deferasirox--a new perspective for patients with iron overload.
Fischer R
Haematologica; 2006 Jul; 91(7):865A. PubMed ID: 16818263
[No Abstract] [Full Text] [Related]
16. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Kontoghiorghes GJ
Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.
Karnon J; Tolley K; Oyee J; Jewitt K; Ossa D; Akehurst R
Curr Med Res Opin; 2008 Jun; 24(6):1609-21. PubMed ID: 18439348
[TBL] [Abstract][Full Text] [Related]
18. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
Karimi M; Azarkeivan A; Zareifar S; Cohan N; Bordbar MR; Haghpanah S
Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
Delea TE; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Pharmacoeconomics; 2007; 25(4):329-42. PubMed ID: 17402805
[TBL] [Abstract][Full Text] [Related]
20. Hypocalcemia in a dialysis patient treated with deferasirox for iron overload.
Yusuf B; McPhedran P; Brewster UC
Am J Kidney Dis; 2008 Sep; 52(3):587-90. PubMed ID: 18534729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
